These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22138164)

  • 1. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.
    Alberati D; Moreau JL; Lengyel J; Hauser N; Mory R; Borroni E; Pinard E; Knoflach F; Schlotterbeck G; Hainzl D; Wettstein JG
    Neuropharmacology; 2012 Feb; 62(2):1152-61. PubMed ID: 22138164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
    Depoortère R; Dargazanli G; Estenne-Bouhtou G; Coste A; Lanneau C; Desvignes C; Poncelet M; Heaulme M; Santucci V; Decobert M; Cudennec A; Voltz C; Boulay D; Terranova JP; Stemmelin J; Roger P; Marabout B; Sevrin M; Vigé X; Biton B; Steinberg R; Françon D; Alonso R; Avenet P; Oury-Donat F; Perrault G; Griebel G; George P; Soubrié P; Scatton B
    Neuropsychopharmacology; 2005 Nov; 30(11):1963-85. PubMed ID: 15956994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotective.
    Priestley T; Marshall GR; Hill RG; Kemp JA
    Br J Pharmacol; 1998 Aug; 124(8):1767-73. PubMed ID: 9756395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.
    Harada K; Nakato K; Yarimizu J; Yamazaki M; Morita M; Takahashi S; Aota M; Saita K; Doihara H; Sato Y; Yamaji T; Ni K; Matsuoka N
    Eur J Pharmacol; 2012 Jun; 685(1-3):59-69. PubMed ID: 22542656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of GlyT1 affect glycine transport via discrete binding sites.
    Mezler M; Hornberger W; Mueller R; Schmidt M; Amberg W; Braje W; Ochse M; Schoemaker H; Behl B
    Mol Pharmacol; 2008 Dec; 74(6):1705-15. PubMed ID: 18815213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus.
    West PJ; Marcy VR; Marino MJ; Schaffhauser H
    Neuroscience; 2009 Dec; 164(2):692-701. PubMed ID: 19660530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists.
    Javitt DC; Balla A; Burch S; Suckow R; Xie S; Sershen H
    Neuropsychopharmacology; 2004 Feb; 29(2):300-7. PubMed ID: 14560321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels.
    Martina M; Gorfinkel Y; Halman S; Lowe JA; Periyalwar P; Schmidt CJ; Bergeron R
    J Physiol; 2004 Jun; 557(Pt 2):489-500. PubMed ID: 15064326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of the NMDA receptor-mediated responses through the activation of the glycine site by microglia secreting soluble factors.
    Hayashi Y; Ishibashi H; Hashimoto K; Nakanishi H
    Glia; 2006 Apr; 53(6):660-8. PubMed ID: 16498631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of interactions between phencyclidine and amphetamine in rodent prefrontal cortex and striatum: implications in NMDA/glycine-site-mediated dopaminergic dysregulation and dopamine transporter function.
    Sershen H; Balla A; Aspromonte JM; Xie S; Cooper TB; Javitt DC
    Neurochem Int; 2008 Jan; 52(1-2):119-29. PubMed ID: 17716783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycine-induced long-term synaptic potentiation is mediated by the glycine transporter GLYT1.
    Igartua I; Solís JM; Bustamante J
    Neuropharmacology; 2007 Jun; 52(8):1586-95. PubMed ID: 17462677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey.
    Eddins D; Hamill TG; Puri V; Cannon CE; Vivian JA; Sanabria-Bohórquez SM; Cook JJ; Morrow JA; Thomson F; Uslaner JM
    Psychopharmacology (Berl); 2014 Feb; 231(3):511-9. PubMed ID: 24051602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide.
    Javitt DC; Sershen H; Hashim A; Lajtha A
    Neuropsychopharmacology; 1997 Sep; 17(3):202-4. PubMed ID: 9272487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between the glycine transporter 1(GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour.
    Singer P; Feldon J; Yee BK
    Eur Neuropsychopharmacol; 2009 Aug; 19(8):571-80. PubMed ID: 19282154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia.
    Robbins MJ; Starr KR; Honey A; Soffin EM; Rourke C; Jones GA; Kelly FM; Strum J; Melarange RA; Harris AJ; Rocheville M; Rupniak T; Murdock PR; Jones DN; Kew JN; Maycox PR
    Brain Res; 2007 Jun; 1152():215-27. PubMed ID: 17434465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related effects of the neuromodulator D-serine on neurotransmission and synaptic potentiation in the CA1 hippocampal area of the rat.
    Junjaud G; Rouaud E; Turpin F; Mothet JP; Billard JM
    J Neurochem; 2006 Aug; 98(4):1159-66. PubMed ID: 16790028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex.
    Konradsson A; Marcus MM; Hertel P; Svensson TH; Jardemark KE
    Synapse; 2006 Aug; 60(2):102-8. PubMed ID: 16715496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subchronic MK-801 treatment and post-weaning social isolation in rats: differential effects on locomotor activity and hippocampal long-term potentiation.
    Ashby DM; Habib D; Dringenberg HC; Reynolds JN; Beninger RJ
    Behav Brain Res; 2010 Sep; 212(1):64-70. PubMed ID: 20382186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.
    Pinard E; Alanine A; Alberati D; Bender M; Borroni E; Bourdeaux P; Brom V; Burner S; Fischer H; Hainzl D; Halm R; Hauser N; Jolidon S; Lengyel J; Marty HP; Meyer T; Moreau JL; Mory R; Narquizian R; Nettekoven M; Norcross RD; Puellmann B; Schmid P; Schmitt S; Stalder H; Wermuth R; Wettstein JG; Zimmerli D
    J Med Chem; 2010 Jun; 53(12):4603-14. PubMed ID: 20491477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZD7288-induced suppression of long-term potentiation was attenuated by exogenous NMDA at the Schaffer collateral-CA1 synapse in the rat in vivo.
    He W; Cheng Z; Fu G; Xu X; Lu Q; Guo L
    Eur J Pharmacol; 2010 Apr; 631(1-3):10-6. PubMed ID: 20064502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.